Spruce Biosciences, Inc. financial data

Symbol
SPRB on Nasdaq
Industry
Pharmaceutical Preparations
Location
611 Gateway Boulevard, Suite 740, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Apr 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 448 % -11%
Debt-to-equity 32.5 % +3.2%
Return On Equity -103 % -96.6%
Return On Assets -77.6 % -95.2%
Operating Margin -1.14K % -122%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42.2M shares +2.63%
Common Stock, Shares, Outstanding 42.2M shares +2.93%
Entity Public Float 18.8M USD -74.9%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 41.3M shares +7.15%
Weighted Average Number of Shares Outstanding, Diluted 41.3M shares +7.15%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 4.91M USD -51.3%
Research and Development Expense 46.4M USD -6.1%
General and Administrative Expense 14.6M USD +15.8%
Operating Income (Loss) -56.2M USD -8%
Net Income (Loss) Attributable to Parent -53M USD -10.7%
Earnings Per Share, Basic -1.29 USD/shares -4.03%
Earnings Per Share, Diluted -1.29 USD/shares -4.03%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 38.8M USD -59.8%
Cash, Cash Equivalents, and Short-term Investments 38.8M USD -59.7%
Accounts Receivable, after Allowance for Credit Loss, Current 15M USD
Other Assets, Current 2.28M USD +15.7%
Assets, Current 44.2M USD -56.7%
Other Assets, Noncurrent 69K USD -88.1%
Assets 45.2M USD -56.5%
Accounts Payable, Current 1.3M USD -61.1%
Accrued Liabilities, Current 12.3M USD -15.6%
Liabilities, Current 15.2M USD -37.7%
Operating Lease, Liability, Noncurrent 736K USD -27.8%
Other Liabilities, Noncurrent 282K USD +19.5%
Liabilities 16.4M USD -40.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -250M USD -26.9%
Stockholders' Equity Attributable to Parent 28.8M USD -62.3%
Liabilities and Equity 45.2M USD -56.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15M USD -26.9%
Net Cash Provided by (Used in) Financing Activities -227K USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 42.2M shares +2.93%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 38.8M USD -59.8%
Deferred Tax Assets, Valuation Allowance 85.3M USD +27.1%
Deferred Tax Assets, Gross 85.5M USD +26.9%
Operating Lease, Liability 1.02M USD -19.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -53M USD -12%
Lessee, Operating Lease, Liability, to be Paid 1.16M USD -22.8%
Operating Lease, Liability, Current 283K USD +12.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 365K USD +3.11%
Lessee, Operating Lease, Liability, to be Paid, Year One 354K USD +3.21%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 140K USD -39.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 376K USD +3.01%
Deferred Tax Assets, Operating Loss Carryforwards 35.5M USD +6.24%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.35M USD +34.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 64K USD -83%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 197K USD -20.9%
Share-based Payment Arrangement, Expense 5.35M USD +15.7%
Interest Expense 307K USD -36.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%